๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guiyang
Clinical trial register · China

Clinical Trials in Guiyang, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca12 Sun Yat-sen University9 The Affiliated Hospital Of Guizhou Medical University6 Peking Union Medical College Hospital5 Institute of Hematology & Blood Diseases Hospital, China4
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Guiyang

180 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
DrugALXN2220
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Not yet open
Early Lumbar Drainage for Intraventricular Hemorrhage
NCT07625449Intraventricular Hemorrhage, Cerebral Hemorrhage
Second Affiliated Hospital of Nanchang University
Not applicable
392
Fuzhou, Jinan, Taizhou, Changde, Dezhou, Ganzhou, Guiyang, Hangzhou
2026-10
Recruiting
A Clinical Trial of TQH3906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis
NCT07724366Psoriasis
DrugsTQH3906·Deucravacitinib
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
400
Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Haikou, Chengde
2026-09-02
Not yet open
AI-Stratified Myopia Control for Children in Remote Areas
NCT07825428Myopia
Shanghai Eye Disease Prevention and Treatment Center
Not applicable
1,600
Guiyang, Shanghai, Kunming
2026-09-01
Not yet open
Zuberitamab in the First Episode of Paediatric Nephrotic Syndrome
NCT07765914Nephrotic Syndrome
DrugZuberitamab
Children's Hospital of Fudan University
Phase 3
120
Shanghai, Changsha, Guiyang, Wuhan, Wuxi, Xiamen
2026-08-20
Recruiting
A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
NCT07784725Obesity or Overweight
DrugAZD6234
AstraZeneca
Phase 3
2,500
Beijing, Cangzhou, Changchun, Changsha, Chengdu, Danyang, Ganzhou, Guiyang
2026-08-19
Not yet open
Yanlishuang Buccal Dropping Pills for Acute Pharyngitis
NCT07761013Acute Pharyngitis
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Not yet open
AI-assisted Rare Disease Diagnosis
NCT07650799Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
1,056
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-08-01
Not yet open
Clinical Study on the Effectiveness of Antibiotics Combined With Bifidobacterium Quadruple Live Tablets in Treating Cirrhosis With Spontaneous Bacterial Peritonitis and Preventing Recurrence
NCT07686861Cirrhosis With Spontaneous Bacterial Peritonitis
Peking University First Hospital
Phase 4
360
Fuyang, Fuzhou, Xiamen, Lanzhou, Guangzhou, Shenzhen, Guigang, Guiyang
2026-07-31
Recruiting
Paclitaxel Oral Solution in Triple Neagtive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
NCT07739485Triple -Negative Breast Cancer
Liu Shu
Phase 1/2
30
Guiyang
2026-07-30
Recruiting
Paclitaxel Oral Solution in HER2-Positive Breast Cancer Neoadjuvant Therapy: A Dose-Finding Study
NCT07739511HER2 + Breast Cancer
Liu Shu
Phase 1/2
30
Guiyang
2026-07-29
Recruiting
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
NCT07720284High-risk Muscle Invasive Urothelial Carcinoma
DrugsDato-DXd·Enfortumab Vedotin·Rilvegostomig·Durvalumab
AstraZeneca
Phase 3
915
Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou
2026-07-16
Recruiting
A Study of MI078 for Postpartum Depression
NCT07721961Postpartum Depression (PPD)
Nanjing Minova Pharmaceutical Co., Ltd.
Phase 3
200
Hefei, Chongqing, Xiamen, Lanzhou, Guangzhou, Zhaoqing, Liuzhou, Guiyang
2026-07-10
Recruiting
Mindfulness Intervention for Emotional Distress (MIED) in Patients With GERD
NCT07667894Gastroesophageal Reflux Disease, Emotional Distress
Xinghua Liu
Not applicable
500
Beijing, Baiyin, Shenzhen, Guiyang, Xingtai, Xinle, Chifeng, Hohhot
2026-06-29
Active, closed
ctDNA Assessment in Endometrial Cancer for Adjuvant Therapy
NCT07681414Endometrial Cancer
Guizhou Provincial People's Hospital
Observational
52
Guiyang
2026-06-27
Not yet open
Artificial Intelligence for Rare Disease Diagnosis
NCT07625436Rare Disorders, Rare Diseases
Peking Union Medical College Hospital
Not applicable
150
Beijing, Cangzhou, Changchun, Dongguan, Foshan, Guiyang, Jilin City, Kunming
2026-06-20
Recruiting
Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NCT07371182Langerhans Cell Histiocytosis (LCH)
DrugLuvometinib
West China Second University Hospital
Not applicable
62
Hefei, Nanning, Guiyang, Zunyi, Nanchang, Xi'an, Chengdu, รœrรผmqi
2026-06-19
Not yet open
Differences in Pelvic Floor Motion Level Among Chinese Women and Construction of an Assessment System
NCT07608146Stress Urinary Incontinence (SUI)
Peking Union Medical College Hospital
Observational
2,000
Hefei, Beijing, Linxia, Qinzhou, Guiyang, Zunyi, Tangshan, Mudanjiang
2026-05-30
Recruiting
Chinese Adults With Kidney Disease
NCT07522099Immunoglobulin A Nephropathy (IgAN), Complement 3 Glomerulopathy (C3G), IC-MPGN
DrugTelitacicept
ADARx Pharmaceuticals, Inc.
Phase 2
30
Shenzhen, Guiyang, Zhengzhou, Baotou, Wuxi, Yantai, Beijing, Shandong
2026-05-21
Recruiting
Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
NCT07379047GIST - Gastrointestinal Stromal Tumor, Advanced
DrugRegorafenib
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3
255
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Shijiazhuang
2026-05-11
Recruiting
A Phase โ… b/โ…กa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.
NCT07593027Pulmonary Arterial Hypertension PAH
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase 1/2
120
Beijing, Jilin City, Fuzhou, Xiamen, Lanzhou, Guangzhou, Guiyang, Zhengzhou
2026-04-30
Recruiting
Evaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
NCT07407803Plexiform Neurofibroma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
177
Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning, Guiyang
2026-03-31
Recruiting
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014Systemic Lupus Erythematosus
Eisai Co., Ltd.
Phase 2
256
Bengbu, Beijing, Chongqing, Guangzhou, Shantou, Nanning, Guiyang, Luoyang
2026-03-31
Recruiting
HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management
NCT07402239Heart Failure
United Innomed(Shanghai) Limited
Not applicable
330
Fuzhou, Lanzhou, Guangzhou, Guiyang, Zhengzhou, Changsha, Nanchang, Shanghai
2026-03-16
Recruiting
ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)
NCT06951646Non Small Cell Lung Cancer, Immune Checkpoint Inhibitors (ICIs)
DrugsBevacizumab·Paclitaxel
Second Xiangya Hospital of Central South University
Phase 2
70
Changsha, Chongqing, Guiyang, Hong Kong, Macao, Nanchang, Nanning, Shenyang
2026-03-10
Recruiting
CAS for Stenosis With High-risk Features for CEA
NCT07370246Carotid Artery Stenosis, Carotid Artery Stenting
Beijing Tiantan Hospital
Not applicable
212
Beijing, Chongqing, Nanning, Guiyang, Shijiazhuang, Xingtai, Wuhan, Hohhot
2026-03-06
Active, closed
Effect of Central Venous Catheterization on Brain Pressure in Acute Brain Injury Patients
NCT07704528Acute Brain Injury, Traumatic Brain Injury, Intracerebral Hemorrhage, Aneurysmal Subarachnoid Hemorrhage (aSAH)
Beijing Tiantan Hospital
Observational
120
Beijing, Guiyang
2026-03-01
Not yet open
Long-Term Safety and Efficacy of HSK39004 Dry Powder Inhaler in COPD
NCT07425210Chronic Obstructive Lung Disease (COLD)
Haisco Pharmaceutical Group Co., Ltd.
Phase 2
300
Guiyang
2026-03
Recruiting
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060Langerhans Cell Histiocytosis (LCH)
DrugsMercaptopurine·Luvometinib·Vincristine·Prednisone
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, รœrรผmqi, Xi'an
2026-02-13
Not yet open
To Evaluate the Safety, Pharmacokinetics, and Efficacy of GB10 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)
NCT07406438Neovascular Age-Related Macular Degeneration (nAMD)
Shenzhen Kexing Pharmaceutical Co., Ltd.
Phase 1
48
Beijing, Guiyang, Zhengzhou, Nanchang, Hangzhou
2026-02-12
Recruiting
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
NCT07392190Overweight, Obesity
DrugEloralintide
Eli Lilly and Company
Phase 3
900
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Hefei, Huzhou
2026-02-10
Not yet open
Dexamethasone Regimens for BPD Prevention in Preterm Infants
NCT07052201Infant, Premature, Bronchopulmonary Dysplasia (BPD)
The Children's Hospital of Zhejiang University School of Medicine
Phase 3
970
Hangzhou, Chengdu, Chongqing, Guangdong, Guangxi, Guiyang, Guizhou, Jilin City
2026-02-01
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
DrugsSonrotoclax·Acalabrutinib·Zanubrutinib·Venetoclax
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
Assessment of the Efficacy and Safety of Injectable TQB2934 (Subcutaneous Injection) in Systemic Light Chain Amyloidosis Patients
NCT07266116Systemic Light Chain Amyloidosis
DrugTQB2934
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1/2
70
Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Guiyang, Baoding, Harbin
2025-12-26
Not yet open
Evaluation of the Efficacy and Safety of TQB2825 Injection Compared to Immunotherapy in the Treatment of Recurrent/Refractory Follicular Lymphoma
NCT07187960Follicular Lymphoma
DrugsTQB2825·Rituximab
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
228
Beijing, Chongqing, Lanzhou, Guangzhou, Guiyang, Haikou, Harbin, Zhengzhou
2025-11
Active, closed
A Translational Study for Phenotyping and Endotyping Chinese Patients With NCFBE
NCT07245407Non-cystic Fibrosis Bronchiectasis
AstraZeneca
Observational
251
Beijing, Chongqing, Quanzhou, Lanzhou, Shenzhen, Zhanjiang, Nanning, Guiyang
2025-10-27
Recruiting
Stereotactic Thrombolysis With Tenecteplase for Supratentorial Intracerebral Hemorrhage
NCT07208097Intracerebral Haemorrhage, Minimally Invasive Treatment
Tongji Hospital
Not applicable
768
Suzhou, Guiyang
2025-10-25
Recruiting
Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
NCT07469267Breast Cancer, Radiotherapy
Fudan University
Not applicable
1,608
Guiyang, Shijiazhuang, Harbin, Wuhan, Changde, Changsha, Dalian, Jinan
2025-10-24
Recruiting
KD Treatment for Super-refractory Status Epilepticus
NCT07496749Super-refractory Status Epilepticus
Xuanwu Hospital, Beijing
Not applicable
84
Hefei, Beijing, Fuzhou, Nanning, Guiyang, Haikou, Shijiazhuang, Harbin
2025-10-20
Recruiting
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
NCT07165028Metabolic Dysfunction-Associated Steatotic Liver Disease
DrugsRetatrutide·Tirzepatide
Eli Lilly and Company
Phase 3
4,500
Beijing, Changsha, Chengdu, Chongqing, Foshan, Fuzhou, Guangzhou, Guiyang
2025-10-15
Not yet open
The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib๏ผšA Prospective, Single-arm, Multicenter, Observational Study
NCT07180459Carcinoma, Hepatocellular Carcinoma
DrugDonafenib
Xuhua Duan
Observational
118
Guiyang, Haikou, Kaifeng, Luohe, Luoyang, Nanyang, Shangqiu, Zhoukou
2025-10-10
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811Transthyretin Amyloid Cardiomyopathy (ATTR CM)
DrugNNC6019-0001
Novo Nordisk A/S
Phase 3
1,280
Hefei, Beijing, Changchun, Fuzhou, Guangzhou, Guiyang, Shijiazhuang, Harbin
2025-10-02
Not yet open
Study on the Effect of Ultra-early Autologous Cranioplasty on Neurological Function Recovery
NCT07183540Cranial Defect
The Affiliated Hospital Of Guizhou Medical University
Not applicable
582
Anshun, Bijie, Guiyang, Kaili, Zunyi, Neijiang
2025-10-01
Recruiting
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG)
NCT07215650Generalized Myasthenia Gravis
DrugCizutamig
Candid Therapeutics
Phase 1
44
Fuzhou, Guangzhou, Guiyang, Zhengzhou, Changchun, Shanghai, Taiyuan, Chengdu
2025-09-16
Recruiting
Study of Efficacy and Safety of Ruxolitinib in Chinese Participants With Corticosteroid-refractory Chronic Graft vs. Host Disease
NCT06824103Graft vs. Host Disease, Chronic Graft vs. Host Disease, Corticosteroid-refractory Chronic Graft vs. Host Disease
DrugRuxolitinib
Novartis Pharmaceuticals
Phase 4
50
Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Zhengzhou, Wuhan, Nanjing
2025-09-09
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsTacabrutideg·Pirtobrutinib
BeOne Medicines
Phase 3
500
Beijing, Fuzhou, Lanzhou, Guangzhou, Jiangmen, Nanning, Guiyang, Shijiazhuang
2025-09-04
Recruiting
Computer-Aided Diagnosis for Hepatocellular Carcinoma Microvascular Invasion
NCT07170345Hepatocellular Carcinoma (HCC), Microvascular Invasion (MVI)
Chinese Academy of Sciences
Observational
400
Fuzhou, Guangzhou, Zhuhai, Nanning, Guiyang, Zhengzhou, Shenyang, Chengdu
2025-09-01
Recruiting
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer
NCT07095023Breast Cancers
DrugsPertuzumab/Trastuzumab·Paclitaxel
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
112
Beijing, Guangzhou, Shantou, Nanning, Guiyang, Haikou, Wenzhou, Shenzhen
2025-08-15
Not yet open
Study on Screening Strategies for Interstitial Lung Abnormalities and Airway Lesions
NCT07023575Interstitial Lung Abnormalities
China-Japan Friendship Hospital
Observational
100,000
Beijing, Shanghai, Changsha, Guiyang, Hangzhou, Henan, Qingdao, Shenyang
2025-08-01
Not yet open
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
NCT07087041Decompensated Cirrhosis, Hepatitis B Virus (HBV) Infection, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Alcohol-Related Liver Disease
Beijing Friendship Hospital
Observational
735
Beijing, Fuzhou, Lanzhou, Foshan, Guangzhou, Zhuhai, Guiyang, Shiyan
2025-07-15
Recruiting
Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer
NCT07008976Metastatic Breast Cancer
DrugsTQB2102·Trastuzumab emtansine
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 3
246
Bengbu, Hefei, Beijing, Fuzhou, Lanzhou, Jiangmen, Nanning, Guiyang
2025-07-07
Recruiting
The AIRTIVITYโ„ข Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
NCT06872892Bronchiectasis
DrugBI 1291583
Boehringer Ingelheim
Phase 3
1,755
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Guiyang, Hangzhou, Hefei
2025-06-09
Active, closed
A Study of SGB-9768 in Patients With Complement-mediated Kidney Diseases
NCT06786338IgA Nephropathy (IgAN), C3 Glomerulopathy, IC-MPGN
DrugSGB-9768
Suzhou Sanegene Bio Inc.
Phase 2
45
Beijing, Changsha, Chengdu, Guiyang, Hangzhou, Shanghai, Yangzhou, Yinchuan
2025-06-06
By invitation
Application of Large Language Models Techniques to Post-ICU Syndrome Management in Critically Ill Patients: A Fully Longitudinal Mixed Study
NCT07141420Post-Intensive Care Syndrome
The Affiliated Hospital Of Guizhou Medical University
Not applicable
90
Guiyang
2025-06-01
Not yet open
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
NCT06986538Advanced Right-sided Colon Cancer, the Extent of Lymph Node Dissection
Sixth Affiliated Hospital, Sun Yat-sen University
Not applicable
1,064
Beijing, Fuzhou, Guangzhou, Qingyuan, Shaoguan, Zhaoqing, Nanning, Guiyang
2025-06-01
Recruiting
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
NCT06749899Nasopharyngeal Cancinoma (NPC), Nasopharyngeal Cancer
DrugsIparomlimab and Tuvonralimab·Gemcitabine·Cisplatin
Sun Yat-Sen University Cancer Center
Phase 3
580
Fuzhou, Dongguan, Foshan, Guangzhou, Zhongshan, Nanning, Guiyang, Wuhan
2025-05-04
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265Non-Proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Phase 3
360
Xuancheng, Beijing, Guangzhou, Shenzhen, Zhuhai, Guiyang, Shijiazhuang, Kaifeng
2025-04-29
Recruiting
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770Severe Hypertriglyceridemia
DrugPlozasiran
Arrowhead Pharmaceuticals
Phase 3
288
Beijing, Guangzhou, Guiyang, Harbin, Luoyang, Nanyang, Zhuzhou, Baotou
2025-04-24
Recruiting
Phase I Study of HSK41959 in Solid Tumors With MTAP Deletion
NCT06968572Advanced Solid Tumors
DrugHSK41959
Haisco Pharmaceutical Group Co., Ltd.
Phase 1
245
Guiyang, Nanjing, Shanghai
2025-04-11
Recruiting
An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome
NCT05066217Lennox Gastaut Syndrome
DrugClemizole HCl
Epygenix
Phase 3
260
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Jinan
2025-04-09
Recruiting
The C-BRIDGE Study: China Bronchiectasis Research Involving Databases, Genomics, and Endotyping
NCT06900062Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
1,500
Guiyang, Changchun, Jinan, Shanghai, Jiaxing
2025-04-06
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
DrugsHLX43 3·HLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Not yet open
Validation of the EQ-5D-Y-3L and EQ-5D-Y-5L for Paediatric Patients in China
NCT06873672Quality of Life (QOL), Patient-Reported Outcome Measures (PROMs), Pneumonia Childhood, Neuroblastoma (NB)
RenJi Hospital
Observational
360
Guiyang
2025-04-01
Recruiting
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
NCT07152041Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
DrugOlverembatinib
Institute of Hematology & Blood Diseases Hospital, China
Phase 3
150
Hefei, Chongqing, Fuzhou, Guangzhou, Guiyang, Wuhan, Changsha, Nanjin
2025-03-28
Recruiting
Efficacy, Safety, Pharmacokinetics of ICP-488 in Patients With Moderate to Severe Plaque Psoriasis
NCT06842199Plaque Psoriasis Patients
Beijing InnoCare Pharma Tech Co., Ltd.
Phase 3
383
Hefei, Wuhu, Beijing, Chongqing, Fuzhou, Guangzhou, Liuzhou, Guiyang
2025-03-20
Active, closed
cOncomitant Left Atrial aPpendage Closure and Pulsed Field ablaTION-Asia
NCT06686485Concomitant Procedures, Atrial Fibrillation, PFA, LAAC
Boston Scientific Corporation
Observational
433
Suzhou, Beijing, Chengdu, Guangzhou, Guiyang, Hangzhou, Jinan, Kunming
2025-03-18
Recruiting
Newly-diagnosed Pediatric T-cell ALL Protocol
NCT06855810Acute Lymphoblastic Leukemia, Childhood Leukemia, Acute Lymphoblastic, T Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
610
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-11
Recruiting
Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)
NCT06880081Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.
Phase 1
12
Guiyang, Nanchang, Jining, Tianjin, Kunming
2025-03-07
By invitation
Intervention Program for Alarm Fatigue in NICU Nurses Based on ABC-X Model
NCT07025863Alert Fatigue, Health Personnel
Guizhou Medical University
Not applicable
33
Guiyang
2025-03-03
Recruiting
Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol
NCT06882057Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
3,000
Hefei, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha
2025-03-03
Not yet open
Inflammatory and Metabolic Prognostic Assessment in Critically Ill Neurological Patients
NCT06849011Stroke Acute, Encephalitis, Non-traumatic Brain Injury
Yan Zhang
Observational
1,185
Beijing, Lanzhou, Guiyang, Zunyi, Tangshan, Shijiazhuang, Hohhot, Suzhou
2025-03-01
Recruiting
A Study of Lianxiaxiaopi Granules in the Treatment of Postprandial Distress Syndrome
NCT06696261Postprandial Distress Syndrome
Tasly Pharmaceutical Group Co., Ltd
Phase 3
342
Beijing, Lanzhou, Guiyang, Shijiazhuang, Xingtai, Baoding, Luoyang, Changchun
2025-02-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
NCT06767514Non-Small Cell Lung Cancer
DrugsPembrolizumab·Bevacizumab
Summit Therapeutics
Phase 3
780
Fuyang, Beijing, Fuzhou, Guangzhou, Nanning, Guiyang, Haikou, Harbin
2025-02-27
Recruiting
Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer
NCT06889688Breast Cancer Stage IV, Triple -Negative Breast Cancer
DrugsEribulin·Apatinib·Tislelizumab
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
246
Guangzhou, Guiyang, Wuhan, Yichang, Changsha, Yongzhou, Shanghai
2025-02-21
Active, closed
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naรฏve Participants With Active Psoriatic Arthritis
NCT06878404Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
552
Beijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guiyang, Linyi
2025-02-21
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
A PILOT TRIAL of a DISPOSABLE INTRACEREBRAL ASPIRATION ENDOSCOPE for the TREATMENT of INTRACEREBRAL HEMATOMA๏ผˆFAST-HET๏ผ‰
NCT06843616Intracerebral Hemorrhage
MicroPort NeuroTech Co., Ltd.
Not applicable
16
Guiyang
2025-02-06
Not yet open
Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor ฮฑ (TNFฮฑ )Inhibitor for the Treatment of Ankylosing Spondylitis
NCT06833112Ankylosing Spondylitis
DrugsSecukinumab·Adalimumab
The Affiliated Hospital Of Guizhou Medical University
Phase 4
10
Guiyang
2025-02
Recruiting
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
NCT06717347Diffuse Large B-Cell Lymphoma
DrugsRituximab Biosimilar·Zilovertamab vedotin·Prednisolone·Methylprednisolone
Merck Sharp & Dohme LLC
Phase 3
1,046
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Guiyang
2025-01-27
Active, closed
A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjรถgren's Syndrome
NCT06684847Primary Sjogrens Disease
DrugEfgartigimod PH20
argenx
Phase 3
631
Bengbu, Hefei, Guangzhou, Nanning, Guiyang, Shijiazhuang, Luoyang, Xinxiang
2025-01-15
Recruiting
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis
NCT06807424Arthritis, Psoriatic
DrugIcotrokinra
Janssen Research & Development, LLC
Phase 3
750
Beijing, Changchun, Changsha, Chengdu, Chongqing, Dongguan, Guangzhou, Guiyang
2025-01-09
Recruiting
Newly-diagnosed Intermediate/High Risk Pediatric B-cell ALL Protocol
NCT06764238Acute Lymphoblastic Leukemia ALL, Childhood Leukemia, Acute Lymphoblastic, B Cell Acute Lymphoblastic Leukemia (B-ALL)
Institute of Hematology & Blood Diseases Hospital, China
Phase 2/3
1,800
Hefei, Fuzhou, Guangzhou, Nanning, Guiyang, Wuhan, Changsha, Nanjing
2025-01-03
Active, closed
Nipocalimab in Moderate to Severe Sjogren's Disease
NCT06741969Sjogrens Syndrome
DrugNipocalimab
Janssen Research & Development, LLC
Phase 3
655
Beijing, Changsha, Changzhou, Chengdu, Dazhou, Ganzhou, Guangzhou, Guiyang
2024-12-04
Recruiting
Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)
NCT03547232Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple
Peking Union Medical College Hospital
Phase 4
1,504
Beijing, Guiyang, Baoding, Harbin, Dengzhou, Nanyang, Huaian, Nantong
2024-12-01
Recruiting
Artificial Intelligence-driven Virtual Standardized Pediatric Patients Trial
NCT06699433Pneumococcal Pneumonia, Rotavirus Enteritis With Hypovolemic Shock, Hand-foot-and-mouth Disease, Acute Appendicitis
Southern Medical University, China
Not applicable
459
Guiyang, Fuzhou, Yisa
2024-12
Active, closed
A Phase III Study in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension in China
NCT06666855Open Angle Glaucoma, Ocular Hypertension
Santen Pharmaceutical Co., Ltd.
Phase 3
345
Beijing, Guangzhou, Guiyang, Hangzhou, Heilongjiang, Jinan, Lanzhou, Luoyang
2024-11-28
Recruiting
A Phase 2 Clinical Study of ABSK061 and ABSK043
NCT06632262HER2-Gastric/Gastroesophageal Junction Cancer, Urothelial Carcinoma, Non-Small Cell Lung Cancer, Solid Tumors
DrugsABSK061·ABSK043·Capox
Abbisko Therapeutics Co, Ltd
Phase 2
202
Guiyang, Shijiazhuang, Harbin, Zhengzhou, Changsha, Nanchang, Shenyang, Jinan
2024-11-13
Active, closed
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
NCT06676319Asthma
DrugsBudesonide/Formoterol·Lunsekimig
Sanofi
Phase 2
556
Beijing, Changchun, Chengde, Chengdu, Foshan, Guangzhou, Guiyang, Hangzhou
2024-11-07
Not yet open
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Recruiting
A Study in Chinese Patients With Acquired Blepharoptosis
NCT06683651Blepharoptosis
Santen Pharmaceutical Co., Ltd.
Phase 3
180
Hefei, Beijing, Shantou, Guiyang, Zhengzhou, Haโ€™erbin, Wuhan, Xiangyang
2024-10-22
Active, closed
Effects of an Individual and Family Self-Management of Fall Prevention Program on Balance Ability and Fall-related Self-efficacy Among Chinese Post-Stroke Individuals
NCT06577662Stroke, Ischemic, Self Efficacy, Fall
Chiang Mai University
Not applicable
60
Guiyang
2024-10-01
By invitation
Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma
NCT06609239Asthma
DrugLunsekimig
Sanofi
Phase 2
900
Beijing, Changchun, Changsha, Chengde, Guangzhou, Guiyang, Hefei, Hohhot
2024-09-30
By invitation
The Trajectory and Influencing Factors of Cognitive Level in ICU Delirium Patients After Transfer Out of the ICU
NCT06674603Cognition Disorder, ICU, Delirium
Zunyi Medical College
Observational
240
Guiyang
2024-09-30
Active, closed
A Study in Patients With Myasthenia Gravis in China
NCT06700616Myasthenia Gravis
AstraZeneca
Observational
1,199
Beijing, Chengdu, Fuzhou, Guangzhou, Guiyang, Harbin, Hebei, Henan
2024-09-26
Recruiting
Study of YK012 in B-cell Acute Lymphoblastic Leukemia
NCT06580301B-cell Acute Lymphoblastic Leukemia
DrugYK012
Excyte Biopharma Ltd
Phase 1/2
46
Guangzhou, Guiyang, Zhengzhou, Xuzhou, Nanchang, Changchun, Dalian, Shenyang
2024-09-25
Recruiting
An Exploratory Study of Individualized Neo-antigen mRNA Cancer Vaccine InnoPCV in Advanced Solid Tumor Treatment
NCT06497010Advanced Solid Tumor
DrugPD-1
The Affiliated Hospital Of Guizhou Medical University
Phase EARLY_PHASE1
40
Guiyang
2024-08-29
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With H-type Hypertension and MTHFR 677 CC/CT Genotype (CSPPT2-CC/CT)
NCT04974138Hypertension, MTHFR 677 CC or CT Genotype, Elevated Plasma Homocysteine (Hcyโ‰ฅ10ยตmol/L), Insufficient Plasma Folate Levels (<12ng/mL)
DrugsAmlodipine besylate·Amlodipine besylate and folic acid·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
32,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
China Stroke Primary Prevention Trial 2 for Participants With Hypertension and MTHFR 677 TT Genotype
NCT04974151Hypertension, MTHFR 677 TT Genotype
DrugsAmlodipine besylate·Amlodipine besylate and folic acid·Amlodipine
Shenzhen Ausa Pharmed Co.,Ltd
Phase 4
24,000
Bengbu, Bozhou, Chizhou, Fuyang, Beijing, Yangjiang, Guiyang, Huaihua
2024-08-22
Recruiting
Clinical Trial Evaluating the Safety and Efficacy of Tumor Thermosensitive Embolic Agent in Transcatheter Arterial Chemoembolization for Primary Liver Cancer
NCT07356531Liver Cancer
JIANGSU SHENMING Medical Technology CO., Ltd
Not applicable
216
Hefei, Beijing, Nanning, Guiyang, Shijiazhuang, Anyang, Luoyang, Zhengzhou
2024-07-29
Recruiting
A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)
NCT06413654Neuromyelitis Optica Spectrum Disorders
DrugB001
Shanghai Jiaolian Drug Research and Development Co., Ltd
Phase 2/3
132
Beijing, Cangzhou, Changsha, Chengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou
2024-07-17
Rows per page Showing 1–100 of 180
1 2 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/guiyang

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 180 of those studies with a site in Guiyang.

How many clinical trials are recruiting in Guiyang?

101 of the 180 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 24 have not yet opened recruitment, 50 are active but closed to new participants, and 5 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guiyang), 180 studies
PhaseStudiesRecruitingShare
Phase 3683537.8%
Not applicable311917.2%
Observational231012.8%
Phase 2201011.1%
Phase 1/21196.1%
Phase 2/31085.6%
Phase 4955%
Phase 1743.9%
Phase EARLY_PHASE1110.6%

Most active sponsors

Lead sponsors with the most studies (Guiyang)
Lead sponsorStudiesRecruiting
AstraZeneca123
Sun Yat-sen University95
The Affiliated Hospital Of Guizhou Medical University63
Peking Union Medical College Hospital52
Huashan Hospital44
Institute of Hematology & Blood Diseases Hospital, China44
Merck Sharp & Dohme LLC43
argenx30
BeOne Medicines32
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.31
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.